Rationale: Evaluation of alternative radionuclides for use in prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is currently focusing on 161 Tb, which may provide advantages by emitting additional Auger and conversion electrons.In this pilot study, we present preliminary dosimetry data [ Tb]Tb-PSMA-617 RLT a direct comparison with 177 Lu]Lu-PSMA-617.Method: Six patients metastatic castration-resistant prostate cancer (mCRPC) underwent treatment Lu]Lu-PSMA-617...

Key biologic effects of the alpha-particle emitter Actinium-225 in comparison to beta-particle Lutetium-177 labeled somatostatin-analogue DOTATOC vitro and vivo were studied evaluate significance γH2AX-foci formation.To determine relative biological effectiveness (RBE) between two isotopes (as - consequence different ionisation-densities along a particle-track), somatostatin expressing AR42J cells incubated with Ac-225-DOTATOC Lu-177-DOTATOC up 48 h viability was analyzed using MTT assay....

Preliminary data from retrospective analyses and recent large randomized controlled trials suggest safety efficacy of radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC). Limited on this modality have been published regarding samples treated everyday practice.We analyzed prospectively collected registry lutetium-177 (177Lu)-PSMA-617 RLT 254 consecutive mCRPC seen academic practice. Since...

Rationale: Despite the promising results of prostate-specific membrane antigen (PSMA)-targeted 177 Lu radioligand therapy in metastatic castration-resistant prostate carcinoma (mCRPC), some patients do not respond and other with initially good response develop resistance to this treatment.In study, we investigated molecular imaging biochemical responses after a single cycle [ 225 Ac]Ac-PSMA-617/[ Lu]Lu-PSMA-617 tandem who had progressed on monotherapy.Methods: Seventeen mCRPC were included...

Terbium-161 is a β-emitting radionuclide that resembles 177Lu in terms of its vivo and vitro chemical pharmacokinetic properties, exhibiting similar behavior with regard to radioligand-specific cell uptake internalization, as well emitting modest fraction photons useful for

The use of 225Ac in prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), either as monotherapy or combination with 177Lu, is a promising approach patients metastatic castration-resistant prostate carcinoma (mCRPC). In this study, we report the efficacy and safety [225Ac]Ac-PSMA-617 augmented [177Lu]Lu-PSMA-617 RLT 177Lu-naive mCRPC (n = 15) poor prognosis (presence visceral metastases, high total tumor burden diffuse bone metastases short PSA doubling time <2...

Abstract An 85-year-old man with advanced metastatic castration-resistant prostate cancer and progression after 8 cycles of 177 Lu–prostate-specific membrane antigen (PSMA)–617 radioligand therapy (RLT) received 1 cycle 161 Tb-PSMA RLT. This one administration 6.5 GBq Tb-PSMA-617 resulted in impressive partial remission a PSA decline by 53.4% (from 474 to 221 ng/mL) concomitant decrease tumor burden on PSMA PET/CT imaging. The presented case provides stunning initial evidence the therapeutic...

Abstract Background Dosimetry is of high importance for optimization patient-individual PSMA-targeted radioligand therapy (PSMA-RLT). The aim our study was to evaluate and compare the feasibility different approaches image-based absorbed dose estimation in terms accuracy effort clinical routine. Methods Whole-body planar images SPECT/CT were acquired from 24 patients 65 cycles at 24h, 48h, ≥96h after administration a mean activity 6.4 GBq [ 177 Lu]Lu-PSMA-617 (range 3–10.9 GBq). performed by...

Background: Radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) is an effective antitumor-treatment in metastatic castration-resistant prostate carcinoma (mCRPC). Concerns of potential nephrotoxicity are based on renal tubular PSMA expression and the resulting radiopharmaceutical retention during RLT, but data confirming clinically significant toxicity still lacking. In this study, patients with significantly impaired baseline kidney function before initiation were...

Abstract Candidates for prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC) frequently have “mismatch” lesions with pronounced 18-fluorodeoxyglucose ([ 18 F]FDG) but attenuated PSMA ligand uptake on positron emission tomography (PET). However, no quantitative criteria yet exist to identify mismatch and predict their response RLT. To define such criteria, we retrospectively analyzed 267 randomly-selected...

In patients with biochemical recurrence of prostate cancer (BCR), preliminary data suggest that prostate-specific membrane antigen (PSMA) ligand radiotracers labeled zirconium-89 (89Zr; half-life ~ 78.41 h), which allow imaging ≥ 24 h post-injection, detect suspicious lesions are missed when using tracers incorporating short-lived radionuclides.To confirm [89Zr]Zr-PSMA-617 positron emission tomography/computed tomography (PET/CT) detection efficacy regarding such lesions, and compare quality...

This pilot study investigates the efficacy and safety profile as well predictive biomarkers of 225 Ac-PSMA-617-augmented 177 Lu-PSMA-617 radioligand therapy (RLT) in a cohort high-risk patients with metastatic castration-resistant prostate cancer (mCRPC), enrolled prospective registry (NCT04833517).

At present, little is known about the molecular imaging-based response assessment of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy with 177Lutetium (177Lu-PSMA-617 RLT) in metastatic castration-resistant prostate cancer (mCRPC). Our study evaluated to RLT using both imaging and biochemical assessments, their potential prediction progression-free survival (PFS). Fifty-one consecutive patients given two cycles at 6-week intervals were analyzed retrospectively....

Despite the promising results of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) in metastatic castration-resistant prostate cancer (mCRPC), some patients show worsening disease during PSMA-RLT. We investigated value combined [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging this setting. In n = 29 mCRPC with after a median four cycles [177Lu]Lu-PSMA-617 RLT, was performed to detect [18F]FDG-avid lesions low or no PSMA expression (mismatch lesions). To evaluate...

Prostate-specific membrane antigen (PSMA)-targeted PET/CT has become increasingly important in the management of prostate cancer, especially localization biochemical recurrence (BCR). PSMA-targeted imaging with long-lived radionuclides as 89Zr (T1/2 = 78.4 h) may improve diagnostics by allowing data acquisition on later time points. In this study, we present our first clinical experience including preliminary biodistribution and dosimetry [89Zr]Zr-PSMA-617 patients BCR cancer.Seven cancer...

We present a case of 69-year-old woman with metastasized small bowel NET G2 initially treated somatostatin analogs (SSA). Disease progression was observed under SSA, and poor tracer uptake on [ 68 Ga]Ga-DOTATOC PET/CT precluded peptide receptor radionuclide therapy (PRRT). Subsequently, evaluation Ga]Ga-NODAGA-LM3 performed, which showed markedly better treatment-sufficient uptake, enabling initiation PRRT 177 Lu]Lu-DOTA-LM3. After 4 cycles, positive response observed. This interesting...

We present a 67-year-old man with inoperable metastatic G3 NET of the pancreas. The lesions were intensely positive in [ 68 Ga]Ga-DOTATOC PET/CT and only weakly supplementary 18 F]-FDG PET/CT. Peptide receptor radionuclide therapy (PRRT) 177 Lu]Lu-DOTA-octreotate, after longstanding efficacy repetitive retreatments over 7 years, eventually resulted disease stabilization without partial regression lesions. After switching PRRT to somatostatin antagonist Lu]Lu-DOTA-LM3, marked response was...

In recent years, radiolabeled tracers targeting prostate-specific membrane antigen (PSMA) have had a tremendous impact on prostate cancer management. Here, we report the formation of radioactive impurities formed during clinical production 177Lu-labeled PSMA-617. We provide compelling evidence that these are result spontaneous, thermally mediated condensation reaction Glu-CO-Lys moiety resulting in three different five-membered ring systems. Density functional theory (DFT) calculations show...

Abstract Background PSMA-targeted radioligand therapy (PSMA-RLT) yielded impressive results in the metastasized castration-resistant prostate carcinoma (mCRPC) setting. High expression of PSMA is essential for successful PSMA-RLT. However, some patients develop [ 18 F]FDG-avid lesions with low or no ([ F]FDG/[ 68 Ga]Ga-PSMA-11 mismatch findings on PET/CT) course treatment. Those are not affected by PSMA-RLT and a change management needed. To enable early detection, possible blood parameters...

Abstract In this work, we analyse passivated emitter and rear cells (PERC), based on wafers made from seed manipulation for artificially controlled defects technique (SMART) monocrystalline silicon, magnetically grown conventional Czochralski (mCz Cz) high‐performance multicrystalline (hpm) silicon. All were processed identically except the hpm wafers, which received an acidic texture instead of random pyramids. The energy conversion efficiency η SMART 21.4 % is similar to mCz (21.5 ) while...